Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus
Endocrinology, Diabetes & Metabolism · 2026-07 · 9 (4)
DOI: 10.1002/edm2.70263 ↗At a glance
Beobachtungsstudie in Endocrinology, Diabetes & Metabolism, published online on 2026-07-06. Written by Yohei Fujita and 5 co-authors. Institution: Department of Diabetes and Endocrinology, Osaka General Medical Center, Osaka, Osaka, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Blood Glucose, Hypoglycemic Agents. 28 references. The full text is freely available (open access, CC BY 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Aims/Introduction Imeglimin is a first‐in‐class oral antidiabetic agent that improves glycemia through dual actions on insulin secretion and sensitivity. However, real‐world data on its long‐term metabolic effects, particularly on endogenous insulin secretion, remain limited. We aimed to evaluate 12‐month longitudinal changes in glycemic indices, an insulin secretion index, and treatment intensity during imeglimin therapy in routine clinical practice. Materials and Methods This retrospective observational study included 73 Japanese patients with type 2 diabetes mellitus who continued imeglimin therapy for approximately 12 months. Hemoglobin A1c (HbA1c) and glycated albumin (GA) were assessed at baseline and follow‐up. Fasting plasma glucose and C‐peptide levels obtained between 10 and 14 months after initiation were used to calculate the fasting C‐peptide index (fCPI). Overall glucose‐lowering treatment intensity was quantified using the medication effect score (MES).
Results
HbA1c significantly decreased from 8.55% ± 1.38% to 7.67% ± 0.99% over 12 months ( p < 0.0001). GA also declined from the early phase after initiation, whereas the GA/HbA1c ratio showed only transient change without sustained differences. The fCPI increased from 1.14 [0.65–1.84] to 1.21 [0.79–2.01] ( n = 69, p = 0.003), and an early increase was observed within 1–2 months. Despite frequent adjustments to background therapies, treatment intensity as assessed by MES did not change significantly.
Conclusions
In a real‐world setting, long‐term imeglimin therapy was associated with sustained glycemic improvement and early as well as sustained numerical changes in an insulin secretion index without an increase in overall treatment intensity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Diabetes and Endocrinology, Osaka General Medical Center, Osaka, Osaka, Japan.
ORCID profiles: Yohei Fujita, Masahiro Hatazaki
Cite
APA
Fujita, Y., Suganami, S., Morita, Y., Matsui, T., Hata, M., & Hatazaki, M. (2026). Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus. Endocrinology, Diabetes & Metabolism, 9(4). https://doi.org/10.1002/edm2.70263
Vancouver
Fujita Y, Suganami S, Morita Y, Matsui T, Hata M, Hatazaki M. Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus. Endocrinology, Diabetes & Metabolism. 2026;9(4). doi:10.1002/edm2.70263
BibTeX
@article{Fujita2026,
author = {Fujita, Yohei and Suganami, Shuji and Morita, Yuka and Matsui, Toshio and Hata, Masahisa and Hatazaki, Masahiro},
title = {Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {4},
doi = {10.1002/edm2.70263}
}
EUVIMED